BRPI0709057C1 - veículo mucoso bioadesivo de lenta liberação, método para preparar um veículo mucoso bioadesivo de lenta liberação, e, uso do veículo mucoso bioadesivo de lenta liberação - Google Patents

veículo mucoso bioadesivo de lenta liberação, método para preparar um veículo mucoso bioadesivo de lenta liberação, e, uso do veículo mucoso bioadesivo de lenta liberação

Info

Publication number
BRPI0709057C1
BRPI0709057C1 BRPI0709057A BRPI0709057A BRPI0709057C1 BR PI0709057 C1 BRPI0709057 C1 BR PI0709057C1 BR PI0709057 A BRPI0709057 A BR PI0709057A BR PI0709057 A BRPI0709057 A BR PI0709057A BR PI0709057 C1 BRPI0709057 C1 BR PI0709057C1
Authority
BR
Brazil
Prior art keywords
vehicle
mucous
slow release
bioadhesive
release bioadhesive
Prior art date
Application number
BRPI0709057A
Other languages
English (en)
Inventor
Lemarchand Caroline
Costantini Dominique
Original Assignee
Bioalliance Pharma
Onxeo S A
Vectans Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioalliance Pharma, Onxeo S A, Vectans Pharma filed Critical Bioalliance Pharma
Publication of BRPI0709057A2 publication Critical patent/BRPI0709057A2/pt
Publication of BRPI0709057B1 publication Critical patent/BRPI0709057B1/pt
Publication of BRPI0709057B8 publication Critical patent/BRPI0709057B8/pt
Publication of BRPI0709057C1 publication Critical patent/BRPI0709057C1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2063—Proteins, e.g. gelatin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Anesthesiology (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

veículo mucoso bioadesivo de lenta liberação, método para preparar um veículo mucoso bioadesivo de lenta liberação, e, uso do veículo mucoso bioadesivo de lenta liberação. um veículo de liberação lenta bioadesivo mucoso, compreendendo um princípio ativo e desprovido de amido, lactose, que pode liberar o princípio ativo por uma duração de mais do que 20 horas. este veículo bioadesivo contém um diluente, um alquilsulfato de metal alcalino, um agente de aglutinação, pelo menos um polímero bioadesivo e pelo menos um polímero de liberação prolongada, bem como um método para sua preparação.
BRPI0709057A 2006-03-24 2007-03-23 veículo mucoso bioadesivo de lenta liberação, método para preparar um veículo mucoso bioadesivo de lenta liberação, e, uso do veículo mucoso bioadesivo de lenta liberação BRPI0709057C1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06290480A EP1837020A1 (en) 2006-03-24 2006-03-24 Mucosal bioadhesive slow release carrier for delivering active principles
EP06290480.0 2006-03-24
PCT/IB2007/001662 WO2007110778A2 (en) 2006-03-24 2007-03-23 Mucosal bioadhesive slow release carrier for delivering active principles

Publications (4)

Publication Number Publication Date
BRPI0709057A2 BRPI0709057A2 (pt) 2011-06-28
BRPI0709057B1 BRPI0709057B1 (pt) 2020-06-30
BRPI0709057B8 BRPI0709057B8 (pt) 2021-02-23
BRPI0709057C1 true BRPI0709057C1 (pt) 2021-05-25

Family

ID=36889131

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0709057A BRPI0709057C1 (pt) 2006-03-24 2007-03-23 veículo mucoso bioadesivo de lenta liberação, método para preparar um veículo mucoso bioadesivo de lenta liberação, e, uso do veículo mucoso bioadesivo de lenta liberação

Country Status (26)

Country Link
US (5) US20090169511A1 (pt)
EP (3) EP1837020A1 (pt)
JP (1) JP5242548B2 (pt)
KR (1) KR101335185B1 (pt)
CN (1) CN101410092B (pt)
AR (1) AR060085A1 (pt)
AT (1) ATE446743T1 (pt)
AU (1) AU2007231029B2 (pt)
BR (1) BRPI0709057C1 (pt)
CA (1) CA2647123C (pt)
CY (1) CY1109723T1 (pt)
DE (1) DE602007002996D1 (pt)
DK (1) DK1998750T3 (pt)
ES (1) ES2335712T3 (pt)
HR (1) HRP20100039T1 (pt)
IL (1) IL193987A (pt)
ME (1) ME01180B (pt)
MX (1) MX2008012186A (pt)
MY (1) MY150072A (pt)
PL (1) PL1998750T3 (pt)
PT (1) PT1998750E (pt)
RS (1) RS51342B (pt)
RU (1) RU2420267C2 (pt)
SI (1) SI1998750T1 (pt)
WO (1) WO2007110778A2 (pt)
ZA (1) ZA200807883B (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1837020A1 (en) 2006-03-24 2007-09-26 Bioalliance Pharma Mucosal bioadhesive slow release carrier for delivering active principles
EP2165706A1 (en) 2008-09-18 2010-03-24 BioAlliance Pharma Treating Inflammatory Pain in Mucosa of the Oral Cavity Using Mucosal Prolonged Release Bioadhesive Therapeutic Carriers.
US8592434B2 (en) 2009-12-09 2013-11-26 Bioalliance Pharma Sa Mucoadhesive buccal tablets for the treatment of orofacial herpes
EP2335690A1 (en) 2009-12-09 2011-06-22 BioAlliance Pharma Mucoadhesive buccal tablets for the treatment of orofacial herpes
EP2509586B1 (en) * 2009-12-09 2018-05-02 Vectans Pharma Mucoadhesive buccal tablets for the treatment of orofacial herpes
JP2014520834A (ja) * 2011-07-15 2014-08-25 フェマロン エス．ペ．エール．エル． Ｈｐｖの治療用の組成物および方法
KR101406106B1 (ko) * 2011-12-19 2014-06-13 동국제약 주식회사 국소 투여용 지속형 치주염 치료제 조성물
EP2814467B1 (en) * 2012-02-19 2020-03-11 Quest Products, LLC Alkalized acacia gum adhesive for oral adhering discs
HK1252120A1 (zh) * 2015-04-29 2019-05-17 Takeda Pharmaceutical Company Limited 抗病毒和抗炎疗法的治疗组合
RU2636185C1 (ru) * 2016-08-03 2017-11-21 Федеральное государственное бюджетное образовательное учреждение высшего образования "Ставропольский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО СтГМУ Минздрава России) Способ лечения хронического генерализованного катарального гингивита в стадии обострения
RU2636173C1 (ru) * 2016-08-03 2017-11-21 Федеральное государственное бюджетное образовательное учреждение высшего образования "Ставропольский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО СтГМУ Минздрава России) Способ лечения хронического генерализованного пародонтита средней степени тяжести в стадии обострения
BR102018008324A2 (pt) * 2018-04-25 2019-11-05 Laboratorios Ferring Ltda composição farmacêutica de uso tópico e processo de fabricação de composição farmacêutica de uso tópico
JP2021523107A (ja) * 2018-04-30 2021-09-02 パーフェクト・デイ・インコーポレイテッド 組換え乳タンパク質ポリマー
WO2020150460A1 (en) * 2019-01-18 2020-07-23 Milne Iii Donald A Micronized aspirin formulation
CN111803468B (zh) * 2020-06-23 2022-12-23 黑龙江天龙药业有限公司 一种靶向、缓释、成膜抑制病毒、细菌的鼻腔喷膜剂及其制备方法
TWI909127B (zh) * 2022-01-24 2025-12-21 聚動分子股份有限公司 含有麩醯胺酸的藥物組成物、製劑及其用途
CN115463102B (zh) * 2022-09-26 2023-11-24 湖北科益药业股份有限公司 一种阿昔洛韦片剂及其制备方法

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58210007A (ja) 1982-06-02 1983-12-07 Takeda Chem Ind Ltd 上部「あ」
DE3320583A1 (de) 1983-06-08 1984-12-13 Dr. Karl Thomae Gmbh, 7950 Biberach Neue galenische zubereitungsformen von oralen antidiabetika und verfahren zu ihrer herstellung
US4849229A (en) 1984-03-26 1989-07-18 Forest Laboratories, Inc. Controlled release solid drug dosage forms based on mixtures of water soluble nonionic cellulose ethers and anionic surfactants
DE3433239A1 (de) 1984-09-11 1986-03-20 Bayer Ag, 5090 Leverkusen Feste arzneizubereitung enthaltend nitrendipin und verfahren zu ihrer herstellung
CA1316110C (en) * 1987-02-27 1993-04-13 Eli Lilly And Company Sustained release matrix formulations
US4792452A (en) 1987-07-28 1988-12-20 E. R. Squibb & Sons, Inc. Controlled release formulation
US4915948A (en) 1987-08-31 1990-04-10 Warner-Lambert Company Tablets having improved bioadhesion to mucous membranes
US5330746A (en) 1988-05-03 1994-07-19 Yissum Research Development Company Of The Hebrew University Of Jerusalem Dental varnish composition, and method of use
US5160737A (en) 1988-05-03 1992-11-03 Perio Products Ltd. Liquid polymer composition, and method of use
US5116603A (en) 1989-01-31 1992-05-26 Yissum Research Development Company Of The Hebrew University Of Jerusalem Oral antifungal preventative, and method of use
NZ234587A (en) * 1989-08-04 1991-11-26 Mcneil Ppc Inc A chewable pharmaceutical tablet of compressed coated granules
EP0451433B1 (en) 1990-04-12 1996-10-23 Janssen Pharmaceutica N.V. Composition of a bioadhesive sustained delivery carrier for drug administration
FR2665357B1 (fr) 1990-07-31 1995-03-31 Aiache Jean Marc Procede de preparation d'une forme galenique bio-adhesive et forme galenique ainsi preparee.
GB9318641D0 (en) 1993-09-08 1993-10-27 Edko Trading Representation Compositions
ATE180971T1 (de) 1994-03-30 1999-06-15 Gs Dev Ab Verwendung von fettsäureester als bioklebstoffe
SI9500173B (sl) * 1995-05-19 2002-02-28 Lek, Trofazna farmacevtska oblika s konstantnim in kontroliranim sproščanjem amorfne učinkovine za enkrat dnevno aplikacijo
US5766620A (en) 1995-10-23 1998-06-16 Theratech, Inc. Buccal delivery of glucagon-like insulinotropic peptides
US5919489A (en) 1995-11-01 1999-07-06 Abbott Laboratories Process for aqueous granulation of clarithromycin
CA2232152C (en) 1995-12-27 2007-02-06 Janssen Pharmaceutica N.V. Bioadhesive solid dosage form
AU6853498A (en) 1997-04-22 1998-11-13 Nippon Kayaku Kabushiki Kaisha Flutamide preparations and method for manufacturing the same
US6248358B1 (en) 1998-08-25 2001-06-19 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets and methods of making and using the same
SE9803239D0 (sv) 1998-09-24 1998-09-24 Diabact Ab Composition for the treatment of acute pain
US6210699B1 (en) * 1999-04-01 2001-04-03 Watson Pharmaceuticals, Inc. Oral transmucosal delivery of drugs or any other ingredients via the inner buccal cavity
US20030224058A1 (en) * 2002-05-24 2003-12-04 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
AU2001227030A1 (en) * 2000-11-22 2002-06-03 Lupin Laboratories Limited Pharmaceutical composition for controlled release of an active ingredient
US20020143058A1 (en) * 2001-01-24 2002-10-03 Taro Pharmaceutical Inductries Ltd. Process for preparing non-hygroscopic sodium valproate composition
CA2447693A1 (en) * 2001-05-31 2002-12-05 Cima Labs Inc. Taste-masking of highly water-soluble drugs
FR2827517B1 (fr) * 2001-07-23 2003-10-24 Bioalliance Pharma Systemes therapeutiques bioadhesifs a liberation prolongee
NZ541167A (en) * 2003-01-31 2008-07-31 Orexo Ab A rapid-acting pharmaceutical composition comprising e.g. fentanyl and particles insoluble in water
EP1837020A1 (en) 2006-03-24 2007-09-26 Bioalliance Pharma Mucosal bioadhesive slow release carrier for delivering active principles

Also Published As

Publication number Publication date
KR101335185B1 (ko) 2013-12-02
BRPI0709057A2 (pt) 2011-06-28
PT1998750E (pt) 2010-01-08
SI1998750T1 (sl) 2010-02-26
BRPI0709057B8 (pt) 2021-02-23
ME01180B (me) 2013-03-20
EP1998750B1 (en) 2009-10-28
EP1998750A2 (en) 2008-12-10
PL1998750T3 (pl) 2010-03-31
EP1837020A1 (en) 2007-09-26
US20100266667A1 (en) 2010-10-21
RU2420267C2 (ru) 2011-06-10
BRPI0709057B1 (pt) 2020-06-30
HRP20100039T1 (hr) 2010-02-28
DE602007002996D1 (de) 2009-12-10
ES2335712T3 (es) 2010-03-31
US20090169511A1 (en) 2009-07-02
EP2216017A1 (en) 2010-08-11
MY150072A (en) 2013-11-29
AU2007231029B2 (en) 2012-02-02
WO2007110778A3 (en) 2008-04-24
KR20090010958A (ko) 2009-01-30
AR060085A1 (es) 2008-05-21
ATE446743T1 (de) 2009-11-15
CA2647123A1 (en) 2007-10-04
US8747896B2 (en) 2014-06-10
CN101410092A (zh) 2009-04-15
CN101410092B (zh) 2012-05-23
JP5242548B2 (ja) 2013-07-24
WO2007110778A2 (en) 2007-10-04
IL193987A (en) 2012-06-28
US8791127B2 (en) 2014-07-29
HK1121692A1 (en) 2009-04-30
RU2008139869A (ru) 2010-04-27
CY1109723T1 (el) 2014-08-13
JP2009531411A (ja) 2009-09-03
CA2647123C (en) 2013-08-06
DK1998750T3 (da) 2010-01-25
ZA200807883B (en) 2011-02-23
US8211466B2 (en) 2012-07-03
AU2007231029A1 (en) 2007-10-04
MX2008012186A (es) 2009-01-16
US20130303556A1 (en) 2013-11-14
US20120329817A1 (en) 2012-12-27
RS51342B (sr) 2011-02-28
US20120326350A1 (en) 2012-12-27
IL193987A0 (en) 2009-09-22

Similar Documents

Publication Publication Date Title
BRPI0709057C1 (pt) veículo mucoso bioadesivo de lenta liberação, método para preparar um veículo mucoso bioadesivo de lenta liberação, e, uso do veículo mucoso bioadesivo de lenta liberação
MX346822B (es) Pro-drogas de compuestos de 2,4-pirimidindiamina y sus usos.
EP4382129A3 (en) Compounds for fast and efficient click release
BRPI0515684A (pt) formulações de cristais injetáveis ativas de longa duração de metabólitos de estradiol, e métodos de utilização das mesmas
BRPI0518334A2 (pt) composiÇço de revestimento, mÉtodo de revestimento, revestimento, e, mÉtodo para preparar uma composiÇço de revestimento
BRPI0415505A (pt) agente terapêutico para mesotelioma
CL2010000188A1 (es) Metodo para el tratamiento de una infeccion en un sujeto que comprende la administracion de 9-[(2,2-dimetil-propilamino)-metil]-minociclina o de una sal de la misma; composicion farmaceutica que comprende dicho compuesto; y su uso.
AR058433A1 (es) Derivado de 1,1-dioxido de 1,4-benzotiazepina ,procedimiento para su preparacion ,medicamentos que comprenden este compuesto y su uso
ECSP099413A (es) COMPUESTOS A BASE DE 4 - fenil - 6 - (2,2,2 - trifluoro - 1 - feniletoxi)pirimidina Y MÉTODOS PARA SU EMPLEO
CL2008002775A1 (es) Uso de un agente de unión a esclerostina para inhibir la resorción ósea.
TW200801813A (en) Resist composition and pattern forming method using the same
BRPI0813140C1 (pt) método para a preparação de ácido desoxicólico (dca) ou um éster desse ou um sal farmaceuticamente aceitável desse e composto intermediário
BRPI0909064A2 (pt) revestimento hidrofílico
EA200700566A1 (ru) Фармацевтические композиции, включающие леветирацетам, и способы их получения
BRPI0718523B8 (pt) Forma de dosagem, e, método para preparar a forma de dosagem
CL2008003057A1 (es) Combinacion farmaceutica que comprende un derivado de purina y un corticoide, agonista de beta-2 adrenoceptor, agente antimuscarinico, entre otros; composicion farmaceutica; y su uso para tratar enfermedades inflamatorias u obstructivas de las vias respiratorias.
NI200500164A (es) Nueva difenilazetidinona con caracteristicas fisiologicas mejoradas, correspondiente metodo de produccion, medicamentos que contienen dicho compuesto y su uso.
BR112012021418A2 (pt) limpador de vasos sanitários e método.
AR050717A1 (es) Composiciones farmaceuticas
BRPI0810130A8 (pt) Composição de bebida, processo para produzir uma composição de bebida, e, uso de uma composição de bebida
BRPI0519070A2 (pt) composiÇço de fator de crescimento de queratinàcito liofilizada, mÉtodos para preparar um fator de crescimento de queratinàcito liofilizado, e para tratar uma doenÇa, e, kit para preparar uma composiÇço farmacÊutica aquosa
CR8912A (es) Formulaciones de acido hidroxamico suberoilanilida y procedimientos para la produccion de las mismas
AR065597A1 (es) Compuesto ester y su uso
BRPI0514584A (pt) método para preparar irbesartan e intermediários do mesmo
MX2007014963A (es) Composicion de liberacion modificada de al menos una forma de venlafaxina.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25D Requested change of name of applicant approved

Owner name: ONXEO S.A (FR)

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25A Requested transfer of rights approved

Owner name: ONXEO S.A (FR) ; VECTANS PHARMA (FR)

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B15G Petition not considered as such [chapter 15.7 patent gazette]

Free format text: A PETICAO 870200024848 DE 20/02/2020 DO TIPO 261 SOLICITA A CORRECAO DO DESPACHO 25.1PUBLICADO NA RPI 2497 DE 13/11/2018 COM A ALEGACAO DA TRANSFERENCIA DA TITULARIDADE TER SIDOTOTAL DO DEPOSITANTE ?ONXEO S.A? PARA O ?VECTANS PHARMA?. ENTRETANTO, COMO PODE SEROBSERVADO NA PETICAO 870180130779 DE 17/09/2018, FORAM ANEXADOS DOCUMENTOS DE CESSAOONDE COMPROVAM A CESSAO PARCIAL DOS DIREITOS DO DEPOSITANTE ?ONXEO S.A? PARA O ?VECTANSPHARMA? EVIDENCIANDO QUE NAO HA ERRO DE PUBLICACAO NA RPI. LOGO, EM VIRTUDE DO DISPOSTO NOSARTS. 218 OU 219 DA LPI (LEI 9279 / 96) DE 14/05/1996, E CONSIDERADA COMO PETICAO NAOCONHECIDA POR NAO SER A PETICAO CORRETA PARA TAL SOLICITACAO.

B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 30/06/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: REF. RPI 2582 DE 30/06/2020 QUANTO AO ENDERECO.

B25A Requested transfer of rights approved

Owner name: VECTANS PHARMA (FR)

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 23/03/2007 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF